Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

DexCom, Inc. (NASDAQ:DXCM ) Wells Fargo 2024 Healthcare Conference September 4, 2024 11:00 AM ET Company Participants Kevin Sayer - Chairman, President, and CEO Jereme Sylvain - CFO Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Lawrence Biegelsen All right. Welcome back everyone.

DexCom, Inc. (DXCM) Wells Fargo 2024 Healthcare Conference (Transcript)

NEW YORK, NY / ACCESSWIRE / September 4, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM LEGAL ALERT: Lose Money on Your DexCom, Inc. Investment? Contact BFA Law about the Pending Class Action before the October Court Deadline

LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 8, 2024 and July 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 21, 2024.

DexCom Inc Is Being Sued For Securities Law Infractions And The Schall Law Firm Wants Investors To Contribute To The Case

EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will spotlight the significant benefits of its innovative CGM technology at an upcoming symposium during the European Association for the Study of Diabetes (EASD) Conference on Monday, 9th September, 1300 – 1430 CEST. The symposium will feature expert panellists from endocrinology Prof. Michael Joubert MD PhD, France, primary care, Prof. S.

Dexcom to Showcase Transformational Impact of Dexcom CGM Technology at the EASD 2024 Conference Symposium

NEW YORK, NY / ACCESSWIRE / September 3, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form?prid=99994&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – DXCM

NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM LEGAL NEWS: A Lawsuit has been Filed Against DexCom, Inc. for Securities Fraud - Investors who Lost Money are Urged to Contact BFA Law (Nasdaq:DXCM)

DexCom stock has fallen 41% this year, but investor sentiment for the maker of glucose monitoring devices could be changing.

DexCom Is the Best Performing Stock in the Nasdaq 100 Tuesday

LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Are Urged To Partake In The Schall Law Firm's Fraud Case Against DexCom Inc.

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), have until October 21, 2024 to seek appointment as lead plaintiff of the DexCom class action lawsuit. Captioned Alonzo v. DexCom, Inc., No. 24-cv-01485 (S.D. Cal.), the DexCom class action lawsuit charges DexCom as well as certain of DexCom's top executives with violations of the Securities Exchange Act of 1934.

DXCM INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company's senior executives.

DXCM STOCK NOTICE: DexCom, Inc. is being Sued for Securities Fraud; Contact BFA Law Now about the Lawsuit if You Lost Money on Your Investment (Nasdaq:DXCM)

NEW YORK, NY / ACCESSWIRE / September 3, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form?prid=99758&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on DexCom, Inc. (DXCM) should contact Levi & Korsinsky about pending Class Action - DXCM

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #DXCM--Robbins LLP is Investigating Allegations that DexCom Inc. (DXCM) Misled Investors Regarding its Business Prospects.

Shareholder Rights Law Firm Robbins LLP Urges DXCM Stockholders with Large Losses to Contact the Firm for Information About the DexCom Inc. Lawsuit

NEW YORK, NY / ACCESSWIRE / September 2, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM STOCK ALERT: BFA Law Alerts DexCom, Inc. Investors that the Company is being Sued for Securities Fraud – Contact the Firm if you Lost Money on Your Investment

LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

DexCom Inc Is Being Sued For Securities Related Infractions And The Schall Law Firm Is Looking For Investor Participation

RADNOR, Pa, Sept. 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is October 21, 2024.

DXCM REMINDER: Kessler Topaz Meltzer & Check, LLP Urges DXCM Investors with Losses to Contact the Firm

DexCom is one of the leaders in an industry with massive growth potential. The company is building a competitive advantage.

Is DexCom a Millionaire-Maker Stock?

NEW YORK, Sept. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), of the important October 21, 2024 lead plaintiff deadline in the securities class action.

ROSEN, LEADING TRIAL ATTORNEYS, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM

The Schall Law Firm, a national shareholder rights litigation firm, DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Stakeholders In DexCom Inc. May Be Entitled To Compensation---Contact The Schall Law Firm About A Lawsuit For Securities Fraud

NEW YORK, Sept. 01, 2024 (GLOBE NEWSWIRE) --  Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company's senior executives.

DXCM STOCK NEWS: A Securities Fraud Class Action has been Filed Against DexCom, Inc. -- Contact BFA Law before October Deadline if You Suffered Losses (Nasdaq:DXCM)

LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders In DexCom Inc. May Be Entitled To Compensation For Losses And Should Reach Out To The Schall Law Firm To Help In A Fraud Case

NEW YORK, NY / ACCESSWIRE / August 31, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM LAWSUIT NOTICE: DexCom, Inc. Investors that Lost Money on their Investment are Encouraged to Contact BFA Law by October 21 about Pending Lawsuit

NEW YORK--(BUSINESS WIRE)---- $DXCM #ClassAction--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired Dexcom Inc. (“Dexcom” or the “Company”) (NASDAQ: DXCM) securities during the period of January 8, 2024 to July 25, 2024, inclusive (“the Class Period”). Investors have until October 21, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Click here to learn.

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Dexcom Inc. (DXCM) Investors

SAN FRANCISCO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges DexCom, Inc. (NASDAQ: DXCM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

DexCom (DXCM) Faces Investor and Analyst Backlash After Revealing Disappointing Growth – Hagens Berman

LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

DexCom Inc Is Being Sued For Securities Law Infractions And The Schall Law Firm Urges Investors To Contribute

RADNOR, Pa. , Aug. 30, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. ("DexCom") (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the "Class Period") The lead plaintiff deadline is October 21, 2024.

News for DexCom Stock (DXCM)